ANDA 201835, held by Sagent Pharmaceuticals. Methylprednisolone Acetate.
As of Nov 19, 2026, ANDA 201835 (Methylprednisolone Acetate), held by Sagent Pharmaceuticals, was first approved by FDA on Jun 27, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension, sterile aqueous suspension, is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 27, 2018 | Original application | Approved |
| Methylprednisolone Acetate20MG/ML · injectable;injection | Methylprednisolone Acetate | Discontinued |
| Methylprednisolone Acetate40MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
| Methylprednisolone Acetate80MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
| Dec 12, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 7, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 27, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters